Genetic and cytokine changes associated with symptomatic stages of CLL

Amit Agarwal, Lawrence Cooke, Christopher Riley, Wenqing Qi, David Mount, Daruka Mahadevan

Producción científica: Articlerevisión exhaustiva

6 Citas (Scopus)

Resumen

The pathogenesis and drug resistance of symptomatic CLL patients involves genetic changes associated with the CLL clone as well as changes within the microenvironment. To further understand these processes, we compared early stage CLL to symptomatic late stage using gene expression and serum cytokine profiling to gain insight of the genetic and microenvironment changes associated with the most severe form of the disease. Patients were classified into low stage (Rai stage 0/I/II) and high stage (Rai stage III/IV). Gene expression profiles were obtained on pretreatment samples using the HG-U133A 2.0 Affymetrix platform. A comparison of low versus high stage CLL revealed a set of 21 genes differentially expressed genes. 15 genes were up regulated in the high stage compared to low stage while 6 genes were down regulated. Analysis of GO molecular function revealed 9 of 21 genes were involved in transcription factor activity. Serum cytokine profiles showed six cytokines to be significantly different in high stage patients. Two chemokines, SDF-1/CXCL12 and uPAR known to be involved in stem cell mobilization and homing were increased in serum of high stage patients. This study has identified therapeutic targets for symptomatic CLL patients.

Idioma originalEnglish (US)
Páginas (desde-hasta)1097-1101
Número de páginas5
PublicaciónLeukemia Research
Volumen38
N.º9
DOI
EstadoPublished - sept 2014
Publicado de forma externa

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Genetic and cytokine changes associated with symptomatic stages of CLL'. En conjunto forman una huella única.

Citar esto